Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
EVAX | US
0.10
2.48%
Healthcare
Biotechnology
30/06/2024
13/04/2026
4.14
4.12
4.24
4.04
Evaxion Biotech A/S a clinical-stage biotech company engages in developing artificial intelligence-powered immunotherapies for cancers bacterial diseases and viral infections. The company develops EVX-01 a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02 a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03 a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1 EVX-B2 and EVX-V1 which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm Denmark.
View LessLow Market Beta (-0.4 to 0.8)
Strong Sharpe Ratio (> 1.2)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
62.2%1 month
61.7%3 months
86.2%6 months
124.0%-
3.57
12.06
8.37
0.69
-0.59
63.35
-
-18.80M
23.09M
23.09M
-
-2.97K
-
-
-802.80
0.90
2.14
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
1.18
Range1M
1.20
Range3M
2.50
Rel. volume
0.48
Price X volume
47.15K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Dyadic International Inc | DYAI | Biotechnology | 0.8593 | 25.33M | -3.54% | n/a | 175.64% |
| INmune Bio Inc | INMB | Biotechnology | 1.24 | 24.59M | 5.08% | n/a | 14.65% |
| NRXP | NRXP | Biotechnology | 2.28 | 24.51M | 2.70% | n/a | -46.73% |
| RenovoRx Inc. Common Stock | RNXT | Biotechnology | 1.02 | 24.47M | 3.52% | n/a | 0.00% |
| Lantern Pharma Inc. | LTRN | Biotechnology | 2.22 | 23.90M | 12.69% | n/a | 0.71% |
| QNRX | QNRX | Biotechnology | 5.92 | 23.56M | 0.34% | n/a | 43.11% |
| Indaptus Therapeutics Inc. Common Stock | INDP | Biotechnology | 2.06 | 21.01M | -2.37% | n/a | 2.12% |
| iBio Inc | IBIO | Biotechnology | 2.2 | 20.10M | 1.85% | n/a | 20.92% |
| Edesa Biotech Inc | EDSA | Biotechnology | 5.9 | 19.16M | 6.88% | n/a | 1.35% |
| DOMH | DOMH | Biotechnology | 3 | 18.83M | 4.17% | n/a | 7.66% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 10.4 | 15.84M | -11.56% | n/a | 204.46% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.8799 | 12.86M | -18.53% | 0.03 | 16.03% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.6 | 11.59M | -0.17% | n/a | 58.43% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.33 | 3.40M | -0.75% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.2276 | 2.17M | -10.25% | n/a | 19.98% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 2.07 | 1.14M | -0.96% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.59 | 0.53 | Cheaper |
| Ent. to Revenue | 63.35 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 12.06 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 86.24 | 72.80 | Par |
| Debt to Equity | 8.37 | -1.23 | Expensive |
| Debt to Assets | 0.69 | 0.25 | Expensive |
| Market Cap | 23.09M | 3.66B | Emerging |